1145 ET - H. Lundbeck's $2.6 billion deal to buy Longboard Pharmaceuticals underscores the industry's growing in interest in developmental and epileptic encephalopathies, or DEEs, and rare epilepsies, analysts at Truist say. In a research note, Truist says the Longboard deal, which carries a 54% premium, has positive derivative read-throughs to the likes of Praxis Precision Medicines, Marinus Pharmaceuticals and Jazz Pharmaceuticals, all of which have drugs approved or in development for DEE. Praxis up 6.3, Marinus up 2.3% and Jazz up 1.1%. (colin.kellaher@wsj.com)
(END) Dow Jones Newswires
October 14, 2024 11:45 ET (15:45 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。